PPARs, nuclear hormone receptors, could be activated by fatty acids and their derivatives and PPAR agonists are beneficial for the treatment of non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and HCC (Cao et al., 2009). The gene discussed is NR0B1; the disease is metabolic dysfunction-associated steatotic liver disease.